• GlucoTrack filed an amended current report to add an independent accountant’s review report and unaudited condensed financial statements for Lokahi Therapeutics for the six months ended June 30, 2026.
• The filing includes a going-concern emphasis, citing recurring operating losses and negative operating cash flow.
• Lokahi reported a net loss of $8.1 million.
• Lokahi reported cash used in operations of $3.62 million.
• Lokahi reported cash and cash equivalents of $53,186.
• The balance sheet showed total assets of $2.5 million.
• The balance sheet showed total liabilities of $9.24 million.
• The balance sheet showed shareholders’ deficit of $6.74 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-040600), on August 28, 2026, and is solely responsible for the information contained therein.